Advertisement


Related Videos

Deborah Collyar: What's In It for Patients?

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Advertisement

Advertisement




Advertisement